Active Site Competition is the Mechanism for the Inhibition of Lipoprotein-associated Phospholipase A by Detergent Micelles or Lipoproteins and for the Efficacy Reduction of Darapladib

Overview

Journal Sci Rep

Specialty Science

Date 2020 Oct 15

PMID 33057060

Citations 2

Authors

Shaoqiu Zhuo

Chong Yuan

Affiliations

Soon will be listed here.

Abstract

Lipoprotein associated phospholipase A (Lp-PLA) has been characterized for its interfacial activation as well as inhibition by detergent micelles and lipoprotein particles. The enzyme has been shown to bind on the surfaces of hydrophobic aggregates, such as detergent micelles, lipoprotein particles and even polystyrene latex nanobeads. Binding to hydrophobic aggregates stimulates the activity of Lp-PLA but may not be the necessary step for catalysis. However, at higher concentrations, detergent micelles, latex nanobeads or lipoprotein particles inhibit Lp-PLA possibly by blocking the access of substrates to the active site. The competition mechanism also blocks inhibitors such as darapladib binding to Lp-PLA and reduces the efficacy of the drug. Darapladib has very low solubility and mainly exists in solutions as complexes with detergents or lipoprotein particles. The inhibition of Lp-PLA by darapladib is dependent on many factors such as concentrations of detergents or lipoproteins, incubation time, as well as the order of mixing reaction components. The in vitro Lp-PLA activity assays used in clinical studies may not accurately reflect the residual Lp-PLA activity in vivo. Darapladib has been found mainly bound on HDL and albumin when it is incubated with human serum. However, Lp-PLA is more sensitive to darapladib when bound on LDL and relatively resistant to darapladib when bound on HDL. Therefore, high cholesterol levels may decrease the efficacy of darapladip and cause the drug to be less effective in high risk patients. Our study will help to design better inhibitors for Lp-PLA. The discoveries also contribute to understanding the mechanism of interfacial activation and inhibition for Lp-PLA and provide a new concept for researchers in building better kinetic model for interfacial enzymes.

Citing Articles

Alternative Targets for sPLA2 Activity: Role of Membrane-Enzyme Interactions.

Alekseeva A, Boldyrev I Membranes (Basel). 2023; 13(7).

PMID: 37504984 PMC: 10384401. DOI: 10.3390/membranes13070618.

Alterations of HDL's to piHDL's Proteome in Patients with Chronic Inflammatory Diseases, and HDL-Targeted Therapies.

Vyletelova V, Novakova M, Paskova L Pharmaceuticals (Basel). 2022; 15(10).

PMID: 36297390 PMC: 9611871. DOI: 10.3390/ph15101278.

References

Mouchlis V, Dennis E . Phospholipase A catalysis and lipid mediator lipidomics. Biochim Biophys Acta Mol Cell Biol Lipids. 2019; 1864(6):766-771. PMC: 6483111. DOI: 10.1016/j.bbalip.2018.08.010. View

Pieterson W, Vidal J, Volwerk J, DE HAAS G . Zymogen-catalyzed hydrolysis of monomeric substrates and the presence of a recognition site for lipid-water interfaces in phospholipase A2. Biochemistry. 1974; 13(7):1455-60. DOI: 10.1021/bi00704a021. View

van Den Berg B, Tessari M, Boelens R, Dijkman R, DE HAAS G, Kaptein R . NMR structures of phospholipase A2 reveal conformational changes during interfacial activation. Nat Struct Biol. 1995; 2(5):402-6. DOI: 10.1038/nsb0595-402. View

Badimon L . New challenges in the etiopathogenesis of atherothrombosis. Cerebrovasc Dis. 2001; 11 Suppl 1:80-4. DOI: 10.1159/000049129. View

Caslake M, Packard C, Suckling K, Holmes S, Chamberlain P, Macphee C . Lipoprotein-associated phospholipase A(2), platelet-activating factor acetylhydrolase: a potential new risk factor for coronary artery disease. Atherosclerosis. 2000; 150(2):413-9. DOI: 10.1016/s0021-9150(99)00406-2. View

Wilensky R, Shi Y, Mohler 3rd E, Hamamdzic D, Burgert M, Li J . Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development. Nat Med. 2008; 14(10):1059-66. PMC: 2885134. DOI: 10.1038/nm.1870. View

Rajman I, Eacho P, Chowienczyk P, Ritter J . LDL particle size: an important drug target?. Br J Clin Pharmacol. 1999; 48(2):125-33. PMC: 2014286. DOI: 10.1046/j.1365-2125.1999.00991.x. View

Rosenson R, Stafforini D . Modulation of oxidative stress, inflammation, and atherosclerosis by lipoprotein-associated phospholipase A2. J Lipid Res. 2012; 53(9):1767-82. PMC: 3413219. DOI: 10.1194/jlr.R024190. View

Zhuo S, Wolfert R, Yuan C . Biochemical differences in the mass and activity tests of lipoprotein-associated phospholipase A explain the discordance in results between the two assay methods. Clin Biochem. 2017; 50(18):1209-1215. DOI: 10.1016/j.clinbiochem.2017.08.019. View

10.

Mora S, Otvos J, Rifai N, Rosenson R, Buring J, Ridker P . Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women. Circulation. 2009; 119(7):931-9. PMC: 2663974. DOI: 10.1161/CIRCULATIONAHA.108.816181. View

11.

Tatulian S . Interfacial Enzymes: Membrane Binding, Orientation, Membrane Insertion, and Activity. Methods Enzymol. 2017; 583:197-230. DOI: 10.1016/bs.mie.2016.09.009. View

12.

Koenig W, Twardella D, Brenner H, Rothenbacher D . Lipoprotein-associated phospholipase A2 predicts future cardiovascular events in patients with coronary heart disease independently of traditional risk factors, markers of inflammation, renal function, and hemodynamic stress. Arterioscler Thromb Vasc Biol. 2006; 26(7):1586-93. DOI: 10.1161/01.ATV.0000222983.73369.c8. View

13.

Thompson A, Gao P, Orfei L, Watson S, Di Angelantonio E, Kaptoge S . Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet. 2010; 375(9725):1536-44. PMC: 2864403. DOI: 10.1016/S0140-6736(10)60319-4. View

14.

Carman G, Deems R, Dennis E . Lipid signaling enzymes and surface dilution kinetics. J Biol Chem. 1995; 270(32):18711-4. DOI: 10.1074/jbc.270.32.18711. View

15.

Hakkinen T, Luoma J, Hiltunen M, Macphee C, Milliner K, Patel L . Lipoprotein-associated phospholipase A(2), platelet-activating factor acetylhydrolase, is expressed by macrophages in human and rabbit atherosclerotic lesions. Arterioscler Thromb Vasc Biol. 1999; 19(12):2909-17. DOI: 10.1161/01.atv.19.12.2909. View

16.

Dashty M, Motazacker M, Levels J, de Vries M, Mahmoudi M, Peppelenbosch M . Proteome of human plasma very low-density lipoprotein and low-density lipoprotein exhibits a link with coagulation and lipid metabolism. Thromb Haemost. 2014; 111(3):518-30. DOI: 10.1160/TH13-02-0178. View

17.

Zhuo S, Yuan C . Characterization of PLAC® tests in the quantization of lipoprotein associated phospholipase A for assessment of cardiovascular diseases. Clin Chim Acta. 2018; 487:222-227. DOI: 10.1016/j.cca.2018.10.007. View

18.

Mohler 3rd E, Ballantyne C, Davidson M, Hanefeld M, Ruilope L, Johnson J . The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized,.... J Am Coll Cardiol. 2008; 51(17):1632-41. DOI: 10.1016/j.jacc.2007.11.079. View

19.

White H, Held C, Stewart R, Tarka E, Brown R, Davies R . Darapladib for preventing ischemic events in stable coronary heart disease. N Engl J Med. 2014; 370(18):1702-11. DOI: 10.1056/NEJMoa1315878. View

20.

Packard C, OReilly D, Caslake M, McMahon A, Ford I, Cooney J . Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. N Engl J Med. 2000; 343(16):1148-55. DOI: 10.1056/NEJM200010193431603. View